RGIN (Regenicin) 3-Year Share Buyback Ratio: 0.00% (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin 3-Year Share Buyback Ratio?

Regenicin RGIN -99.00% 3-Year Share Buyback Ratio is 0.00 as of Mar. 2023.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Regenicin's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Regenicin's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 13 years, Regenicin's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was 0.00%. And the median was 0.00%.

RGIN's 3-Year Share Buyback Ratio is not ranked *
in the Biotechnology industry.
Industry Median: -11.8
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Regenicin (OTCPK:RGIN) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Regenicin 3-Year Share Buyback Ratio Related Terms

RGIN vs NOVNQ, TMBRQ, RGRX: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Regenicin's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenicin 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Regenicin's 3-Year Share Buyback Ratio falls into.


Regenicin 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of 0.00 mean?
Regenicin (RGIN) has a 3-Year Share Buyback Ratio of 0.00 as of Mar. 2023. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Regenicin and its competitors.
Is Regenicin's 3-Year Share Buyback Ratio too high?
Regenicin's current 3-Year Share Buyback Ratio is 0.00.
How does Regenicin's 3-Year Share Buyback Ratio compare to NOVNQ and TMBRQ?
Regenicin's 3-Year Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Regenicin and its competitors. Regenicin's current 3-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current 3-Year Share Buyback Ratio of 0.00. The current 3-Year Share Buyback Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Regenicin (RGIN), the current 3-Year Share Buyback Ratio is 0.00 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.